期刊文献+

Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging

Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging
下载PDF
导出
摘要 AIM: To establish a prognostic formula that distinguishes non-hypervascular hepatic nodules(NHNs) with higher aggressiveness from less hazardous one. METHODS: Seventy-three NHNs were detected in gadolinium ethoxybenzyl diethylene-triamine-pentaaceticacid magnetic resonance imaging(Gd-EOB-DTPA-MRI) study and confirmed to change 2 mm or more in size and/or to gain hypervascularity. All images were interpreted independently by an experienced, board-certified abdominal radiologist and hepatologist; both knew thatthe patients were at risk for hepatocellular carcinoma development but were blinded to the clinical information. A formula predicting NHN destiny was developed using a generalized estimating equation model with thirteen explanatory variables: age, gender, background liver diseases, Child-Pugh class, NHN diameter, T1-weighted imaging/T2-weighted imaging detectability, fat deposition, lower signal intensity in arterial phase, lower signal intensity in equilibrium phase, α-fetoprotein, des-γ-carboxy prothrombin, α-fetoprotein-L3, and coexistence of classical hepatocellular carcinoma. The accuracy of the formula was validated in bootstrap samples that were created by resampling of 1000 iterations. RESULTS: During a median follow-up period of 504 d, 73 NHNs with a median diameter of 9 mm(interquartile range: 8-12 mm) grew or shrank by 68.5%(fifty nodules) or 20.5%(fifteen nodules), respectively, whereas hypervascularity developed in 38.4%(twenty eight nodules). In the fifteen shrank nodules, twelve nodules disappeared, while 11.0%(eight nodules) were stable in size but acquired vascularity. A generalized estimating equation analysis selected five explanatories from the thirteen variables as significant factors to predict NHN progression. The estimated regression coefficients were 0.36 for age, 6.51 for lower signal intensity in arterial phase, 8.70 or 6.03 for positivity of hepatitis B virus or hepatitis C virus, 9.37 for des-γ-carboxy prothrombin, and-4.05 for fat deposition. A formula incorporating the five coefficients revealed sensitivity, specificity, and accuracy of 88.0%, 86.7%, and 87.7% in the formulating cohort, whereas these of 87.2% ± 5.7%, 83.8% ± 13.6%, and 87.3% ± 4.5% in the bootstrap samples. CONCLUSION: These data suggest that the formula helps Gd-EOB-DTPA-MRI detect a trend toward hepatocyte transformation by predicting NHN destiny. AIM: To establish a prognostic formula that distinguishes non-hypervascular hepatic nodules(NHNs) with higher aggressiveness from less hazardous one. METHODS: Seventy-three NHNs were detected in gadolinium ethoxybenzyl diethylene-triamine-pentaaceticacid magnetic resonance imaging(Gd-EOB-DTPA-MRI) study and confirmed to change 2 mm or more in size and/or to gain hypervascularity. All images were interpreted independently by an experienced, board-certified abdominal radiologist and hepatologist; both knew thatthe patients were at risk for hepatocellular carcinoma development but were blinded to the clinical information. A formula predicting NHN destiny was developed using a generalized estimating equation model with thirteen explanatory variables: age, gender, background liver diseases, Child-Pugh class, NHN diameter, T1-weighted imaging/T2-weighted imaging detectability, fat deposition, lower signal intensity in arterial phase, lower signal intensity in equilibrium phase, α-fetoprotein, des-γ-carboxy prothrombin, α-fetoprotein-L3, and coexistence of classical hepatocellular carcinoma. The accuracy of the formula was validated in bootstrap samples that were created by resampling of 1000 iterations. RESULTS: During a median follow-up period of 504 d, 73 NHNs with a median diameter of 9 mm(interquartile range: 8-12 mm) grew or shrank by 68.5%(fifty nodules) or 20.5%(fifteen nodules), respectively, whereas hypervascularity developed in 38.4%(twenty eight nodules). In the fifteen shrank nodules, twelve nodules disappeared, while 11.0%(eight nodules) were stable in size but acquired vascularity. A generalized estimating equation analysis selected five explanatories from the thirteen variables as significant factors to predict NHN progression. The estimated regression coefficients were 0.36 for age, 6.51 for lower signal intensity in arterial phase, 8.70 or 6.03 for positivity of hepatitis B virus or hepatitis C virus, 9.37 for des-γ-carboxy prothrombin, and-4.05 for fat deposition. A formula incorporating the five coefficients revealed sensitivity, specificity, and accuracy of 88.0%, 86.7%, and 87.7% in the formulating cohort, whereas these of 87.2% ± 5.7%, 83.8% ± 13.6%, and 87.3% ± 4.5% in the bootstrap samples. CONCLUSION: These data suggest that the formula helps Gd-EOB-DTPA-MRI detect a trend toward hepatocyte transformation by predicting NHN destiny.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第15期4583-4591,共9页 世界胃肠病学杂志(英文版)
关键词 Hepatocellular carcinoma Magnetic resonanceimaging Ethoxybenzyl MOIETY Non-hypervascular hepaticnodule Fate prediction Hepatocellular carcinoma Magnetic resonance imaging Ethoxybenzyl moiety Non-hypervascular hepatic nodule Fate prediction
  • 相关文献

参考文献15

  • 1Bruix J, Sherman M. Management of hepatocellular carcinoma: anupdate. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI:10.1002/hep.24199].
  • 2Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, NegishiC, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOBDTPAas a contrast agent in MR imaging of the hepatobiliarysystem. Radiology 1992; 183: 59-64 [PMID: 1549695].
  • 3Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE,Tombach B, Hesse T, Berns T, Peters PE. Phase II clinicalevaluation of Gd-EOB-DTPA: dose, safety aspects, and pulsesequence. Radiology 1996; 199: 177-183 [PMID: 8633143].
  • 4Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T,Wolf KJ, Weinmann HJ, Lange L. Phase I clinical evaluation ofGd-EOB-DTPA as a hepatobiliary MR contrast agent: safety,pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792[PMID: 7754011].
  • 5Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W,Kozaka K, Yoneda N, Yamashita T, Kaneko S, Nakanuma Y.Hepatocellular carcinoma: signal intensity at gadoxetic acidenhancedMR Imaging-- correlation with molecular transportersand histopathologic features. Radiology 2010; 256: 817-826[PMID: 20663969 DOI: 10.1148/radiol.10092214].
  • 6Vogl TJ, Kümmel S, Hammerstingl R, Schellenbeck M,Schumacher G, Balzer T, Schwarz W, Müller PK, Bechstein WO,Mack MG, S-llner O, Felix R. Liver tumors: comparison of MRimaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200: 59-67 [PMID: 8657946].
  • 7Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, BolondiL. Contribution of the hepatobiliary phase of Gd-EOB-DTPAenhancedMRI to Dynamic MRI in the detection of hypovascularsmall (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233-1242[PMID: 21293864 DOI: 10.1007/s00330-010-2030-1].
  • 8Kim MJ. Current limitations and potential breakthroughs for theearly diagnosis of hepatocellular carcinoma. Gut Liver 2011; 5:15-21 [PMID: 21461067 DOI: 10.5009/gnl.2011.5.1.15].
  • 9Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, TakeharaY, Kamura T, Gabata T, Murakami T, Ito K, Hirohashi S, NishieA, Saito Y, Onaya H, Kuwatsuru R, Morimoto A, Ueda K,Kurauchi M, Breuer J. Detection and characterization of focal liverlesions: a Japanese phase III, multicenter comparison betweengadoxetic acid disodium-enhanced magnetic resonance imagingand contrast-enhanced computed tomography predominantly inpatients with hepatocellular carcinoma and chronic liver disease.Invest Radiol 2010; 45: 133-141 [PMID: 20098330 DOI: 10.1097/RLI.0b013e3181caea5b].
  • 10Akai H, Matsuda I, Kiryu S, Tajima T, Takao H, WatanabeY, Imamura H, Kokudo N, Akahane M, Ohtomo K. Fate ofhypointense lesions on Gd-EOB-DTPA-enhanced magneticresonance imaging. Eur J Radiol 2012; 81: 2973-2977 [PMID:22280873 DOI: 10.1016/j.ejrad.2012.01.007].

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部